SECsense Logo

NewAmsterdam Pharma 8-K Report: Stock Insights & Compliance Overview

$NAMS
Form 8-K
Filed on: 2025-01-10
Source
NewAmsterdam Pharma 8-K Report: Stock Insights & Compliance Overview

Based on the provided XML section of the financial report, here are the key pieces of information extracted:

  1. Company Identification:
  • Name: NewAmsterdam Pharma Company N.V.
  • CIK (Central Index Key): 0001936258
  • SEC Filing Type: 8-K
  • Filing Date: January 10, 2025
  1. Stock Information:
  • Ordinary Shares:
    • Nominal value: €0.12 per share
    • Ticker Symbol: NAMS (traded on NASDAQ)
  • Warrants:
    • Ticker Symbol: NAMSW (traded on NASDAQ)
  1. Reporting Context:
  • The report covers a specific date: January 10, 2025.
  • The reporting appears to include multiple classes of stock including:
    • Common Stock
    • Warrants
  1. Location and Contact Information:
  • Address: Gooimeer 2-35, Naarden, NL 1411 DC
  • Phone: +31 (0) 35 206 2971
  1. XBRL and GAAP Compliance:
  • The filing is structured in XBRL format and adheres to US GAAP standards, indicating that the report is compliant with standardized financial reporting practices.

Insights:

  • This filing appears to be a routine 8-K report, which typically contains important information that may affect the company's financial condition or operations.
  • The presence of both ordinary shares and warrants suggests that the company may be engaging in activities that could affect equity structure or funding strategies.
  • The nominal value of ordinary shares is relatively low, which could indicate a strategy aimed at making shares more accessible to investors.
  • The listing on NASDAQ and the mention of warrants may indicate a focus on attracting investment through various equity instruments.

Overall, this section of the report provides a snapshot of NewAmsterdam Pharma Company's stock structure and relevant contact information, which could be essential for investors and analysts monitoring the company's developments.